BR0107210A - Sais de amino mono- ou di-orgânicas, sais de mono- e di-aminoãcidos e sais de ésteres de mono- e di-aminoácidos da prõ-droga fosfato de combretastatina a-4 - Google Patents

Sais de amino mono- ou di-orgânicas, sais de mono- e di-aminoãcidos e sais de ésteres de mono- e di-aminoácidos da prõ-droga fosfato de combretastatina a-4

Info

Publication number
BR0107210A
BR0107210A BR0107210-2A BR0107210A BR0107210A BR 0107210 A BR0107210 A BR 0107210A BR 0107210 A BR0107210 A BR 0107210A BR 0107210 A BR0107210 A BR 0107210A
Authority
BR
Brazil
Prior art keywords
mono
salts
combretastatin
amino
amino acid
Prior art date
Application number
BR0107210-2A
Other languages
English (en)
Other versions
BRPI0107210B1 (pt
Inventor
John J Venit
Mandar V Dali
Manisha M Dali
Yande Huang
Charles E Dahlheim
Raviadra W Tejwani
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0107210A publication Critical patent/BR0107210A/pt
Publication of BRPI0107210B1 publication Critical patent/BRPI0107210B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"SAIS DE AMINA MONO-OU DI-ORGâNICAS, SAIS DE MONO- E DI-AMINOáCIDOS E SAIS DE éSTERES DE MONO- E DI-AMINOáCIDOS DA PRó-DROGA FOSFATO DE COMBRETASTATINA A-4". São fornecidos novos e úteis sais de pró-droga de combretastatina A-4 que aumentam a solubilidade de combretastatina A-4, regeneram facilmente a combretastatina A-4 in vivo em condições fisiológicas normais, e produzem produtos fisiologicamente toleráveis como resultado da regeneração de combretastatina A-4.
BRPI0107210-2A 2000-09-14 2001-09-12 Mono- or di-organic amine salts, mono- and di-aminoic acid salts and salts of progrogen mono- and diamino acid esters combretastatin phosphate a-4, pharmaceutical compositions and process for preparing the same BRPI0107210B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23256800P 2000-09-14 2000-09-14
US60/232,568 2000-09-14
US25192100P 2000-12-07 2000-12-07
US60/251,921 2000-12-07
PCT/US2001/028401 WO2002022626A1 (en) 2000-09-14 2001-09-12 Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds

Publications (2)

Publication Number Publication Date
BR0107210A true BR0107210A (pt) 2003-02-25
BRPI0107210B1 BRPI0107210B1 (pt) 2017-09-26

Family

ID=26926130

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0107210-2A BRPI0107210B1 (pt) 2000-09-14 2001-09-12 Mono- or di-organic amine salts, mono- and di-aminoic acid salts and salts of progrogen mono- and diamino acid esters combretastatin phosphate a-4, pharmaceutical compositions and process for preparing the same

Country Status (26)

Country Link
US (2) US6670344B2 (pt)
EP (1) EP1320534B1 (pt)
JP (2) JP4149804B2 (pt)
KR (1) KR100858464B1 (pt)
CN (1) CN100338077C (pt)
AR (1) AR030727A1 (pt)
AT (1) ATE293630T1 (pt)
AU (2) AU785183B2 (pt)
BR (1) BRPI0107210B1 (pt)
CA (1) CA2422359C (pt)
DE (1) DE60110249T2 (pt)
EE (1) EE200200249A (pt)
ES (1) ES2241872T3 (pt)
HK (1) HK1052356B (pt)
HU (1) HU229055B1 (pt)
IL (3) IL149601A0 (pt)
MX (1) MXPA03002209A (pt)
NO (1) NO329973B1 (pt)
NZ (1) NZ524926A (pt)
PE (1) PE20020445A1 (pt)
PT (1) PT1320534E (pt)
RS (1) RS50309B (pt)
SK (1) SK287117B6 (pt)
TW (1) TWI250163B (pt)
UY (1) UY26935A1 (pt)
WO (1) WO2002022626A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019944D0 (en) * 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US20050153939A1 (en) * 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
WO2002086869A1 (fr) * 2001-04-19 2002-10-31 Sony Corporation Appareil lecteur/enregistreur numerique
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
CA2453442C (en) * 2001-07-13 2011-02-01 Oxigene, Inc. Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
CN100365000C (zh) * 2003-09-18 2008-01-30 雍智全 Combretastatin A-4磷酰胆碱类前体药物以及其合成与应用
MXPA06007215A (es) 2003-12-23 2006-08-18 Schering Plough Ltd Profarmaco florfenicol con mejor solubilidad en agua.
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
WO2006138427A2 (en) 2005-06-14 2006-12-28 Baylor University Combretastatin analogs with tubulin binding activity
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
BRPI0620040A2 (pt) * 2005-12-19 2011-10-25 Methylgene Inc inibidores de histona desacetilase para realçar a atividade de agentes antifúngicos
MX349787B (es) 2006-04-04 2017-08-11 Kg Acquisition Llc Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
CA2672192A1 (en) 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008103415A2 (en) * 2007-02-22 2008-08-28 Oxigene, Inc. Methods of preparing phosphoric acids of combretastatin and derivatives thereof
WO2008109076A1 (en) * 2007-03-02 2008-09-12 Oxigene, Inc. Methods for enhancing the efficacy of vascular disrupting agents
CN101801348A (zh) * 2007-06-22 2010-08-11 百时美施贵宝公司 含有阿扎那韦的压片组合物
CN101778624A (zh) * 2007-06-22 2010-07-14 百时美施贵宝公司 含有阿扎那韦的压片组合物
JP2010530890A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
PT2178513E (pt) * 2007-06-22 2011-05-31 Bristol Myers Squibb Co Composi??es em comprimido que cont?m atazanavir
EP2219451B1 (en) 2007-11-21 2014-11-12 Oxigene, Inc. Method for treating hematopoietic neoplasms
CN102757338B (zh) * 2012-02-29 2015-02-25 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸氨基酸乙酯盐、制备方法及其用途
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
DE3438386A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Phosphorsaeurevinylbenzylester, ihre herstellung und verwendung
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
DE19506885A1 (de) 1995-02-17 1996-08-22 Schering Ag Neue Borneolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
WO1999035159A1 (en) * 1998-01-08 1999-07-15 Brigham & Women's Hospital, Inc. Lymphoma/leukemia oncogene, oncoprotein and methods of use
US7018987B1 (en) * 1998-01-09 2006-03-28 Arizona Broad of Regents acting for and on behalf of Arizona State University Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
KR100858464B1 (ko) 2008-09-16
AU9077101A (en) 2002-03-26
US6670344B2 (en) 2003-12-30
BRPI0107210B1 (pt) 2017-09-26
IL149601A (en) 2007-06-17
US20040054212A1 (en) 2004-03-18
UY26935A1 (es) 2002-04-26
WO2002022626A8 (en) 2002-04-18
IL176088A0 (en) 2006-10-05
AU785183B2 (en) 2006-10-19
DE60110249T2 (de) 2006-03-02
NO20022270D0 (no) 2002-05-13
MXPA03002209A (es) 2004-03-02
ES2241872T3 (es) 2005-11-01
US6855702B2 (en) 2005-02-15
EP1320534B1 (en) 2005-04-20
YU34802A (sh) 2005-07-19
PT1320534E (pt) 2005-08-31
JP2008195740A (ja) 2008-08-28
US20020072507A1 (en) 2002-06-13
CA2422359C (en) 2008-12-23
SK287117B6 (sk) 2009-12-07
HK1052356B (zh) 2008-06-27
AR030727A1 (es) 2003-09-03
KR20020063187A (ko) 2002-08-01
NO329973B1 (no) 2011-01-31
TWI250163B (en) 2006-03-01
EE200200249A (et) 2003-06-16
WO2002022626A1 (en) 2002-03-21
DE60110249D1 (de) 2005-05-25
ATE293630T1 (de) 2005-05-15
IL149601A0 (en) 2002-11-10
CN1392876A (zh) 2003-01-22
SK6722002A3 (en) 2002-11-06
NZ524926A (en) 2004-10-29
CA2422359A1 (en) 2002-03-21
CN100338077C (zh) 2007-09-19
PE20020445A1 (es) 2002-05-18
HUP0204423A3 (en) 2005-02-28
NO20022270L (no) 2002-07-01
AU2007200218A1 (en) 2007-02-08
JP4149804B2 (ja) 2008-09-17
HK1052356A1 (en) 2003-09-11
RS50309B (sr) 2009-09-08
JP2004509128A (ja) 2004-03-25
HUP0204423A2 (en) 2003-05-28
HU229055B1 (hu) 2013-07-29
EP1320534A1 (en) 2003-06-25

Similar Documents

Publication Publication Date Title
BR0107210A (pt) Sais de amino mono- ou di-orgânicas, sais de mono- e di-aminoãcidos e sais de ésteres de mono- e di-aminoácidos da prõ-droga fosfato de combretastatina a-4
BR0112538A (pt) Sais estáveis de ácido o-acetilsalicìlico com aminoácidos básicos
HRP20020428B1 (en) Bicyclic amino acids as pharmaceutical agents
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
BR0113520A (pt) Processo de preparação de ácidos n-aril-antranìlicos e seus derivados
SE0002202D0 (sv) New peptides
BRPI0418133A2 (pt) pró-fármaco de florfenicol tendo solubilidade em água melhorada
TW200716138A (en) Stable active compound complex of salts of O-acetylsalicylic acid with basic amino acids and glycine
DE50306796D1 (de) Dermales applikationssystem für aminolävulinsäure-derivate
ES2171923T3 (es) Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos.
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
DK1476470T3 (da) Stivelsesderivater, stivelse-aktivstof-konjugater, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemidler
ES2184302T3 (es) Procedimiento para la preparacion del acido 1,4,7,10-tetraazaciclododecano-1,4,7-triacetico y derivados del mismo.
TNSN07228A1 (en) Manufacture process of organic compounds
BR0307009A (pt) Sais estáveis de ácido o-acetilsalicìlico com aminoácidos básicos ii
BR0008368A (pt) Derivados fenilalaninol
FR2870735A1 (fr) Composition pour le traitement de matieres keratiniques comprenant un compose polycarboxylique particulier et un tensioactif mono-ou poly-glycerole et procedes la mettant en oeuvre
CO5021190A1 (es) Agentes terapeuticos
ZA200203832B (en) Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts.
AU2003301513A1 (en) Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
BR0009783A (pt) Sais de ácido fosfórico de uma diamina aromática
TH65441A (th) เกลือมอนอ-และได-ออกแกนิกแอมีน, เกลือมอนอ-และได-แอมิโนแอซิด, และเกลือของมอนอ-และได-แอมิโนแอซิดเอสเทอร์ของคอมบรีแทสแททิน a-4 ฟอสเฟตโปรดรัก
ECSP992942A (es) Estimulacion hematopoyetica
CO4940433A1 (es) Gliconjugados de 20(s)-camptotecina y procedimiento para su obtencion
UY26674A1 (es) Derivados de pirrolidina y piperidina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.